Literature DB >> 24900247

First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.

Ulrike E Hille1, Christina Zimmer1, Carsten A Vock1, Rolf W Hartmann1.   

Abstract

Outgoing from an etomidate-based design concept, we succeeded in the development of a series of highly active and selective inhibitors of CYP11B1, the key enzyme of cortisol biosynthesis, as potential drugs for the treatment of Cushing's syndrome and related diseases. Thus, compound 33 (IC50 = 152 nM) is the first CYP11B1 inhibitor showing a rather good selectivity toward the most important steroidogenic CYP enzymes aldosterone synthase (CYP11B2), the androgen-forming CYP17, and aromatase (estrogen synthase, CYP19).

Entities:  

Keywords:  CYP11B1 inhibitor; CYP11B2; CYP17; CYP19; Cushing's syndrome; etomidate; steroid hormone biosynthesis; steroid-11β-hydroxylase

Year:  2010        PMID： 24900247      PMCID： PMC4018151          DOI： 10.1021/ml100071j

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  33 in total

1.  Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.

Authors:  Francesco Leonetti; Angelo Favia; Angela Rao; Rosaria Aliano; Anja Paluszcak; Rolf W Hartmann; Angelo Carotti
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

2.  5-Phenyl substituted 1-methyl-2-pyridones and 4'-substituted biphenyl-4-carboxylic acids. synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2.

Authors:  Franck Picard; Tobias Schulz; Rolf W Hartmann
Journal:  Bioorg Med Chem       Date:  2002-02       Impact factor: 3.641

3.  1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase.

Authors:  C Jacobs; M Frotscher; G Dannhardt; R W Hartmann
Journal:  J Med Chem       Date:  2000-05-04       Impact factor: 7.446

4.  Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2.

Authors:  F Picard; E Baston; W Reichert; R W Hartmann
Journal:  Bioorg Med Chem       Date:  2000-06       Impact factor: 3.641

5.  Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.

Authors:  Marieke Voets; Iris Antes; Christiane Scherer; Ursula Müller-Vieira; Klaus Biemel; Catherine Barassin; Sandrine Marchais-Oberwinkler; Rolf W Hartmann
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

6.  New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.

Authors:  Ilse M Zolle; Michael L Berger; Friedrich Hammerschmidt; Stefanie Hahner; Andreas Schirbel; Biljana Peric-Simov
Journal:  J Med Chem       Date:  2008-03-19       Impact factor: 7.446

7.  Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells.

Authors:  Peter B Ehmer; Matthias Bureik; Rita Bernhardt; Ursula Müller; Rolf W Hartmann
Journal:  J Steroid Biochem Mol Biol       Date:  2002-06       Impact factor: 4.292

Review 8.  An overview on 5alpha-reductase inhibitors.

Authors:  Saurabh Aggarwal; Suresh Thareja; Abhilasha Verma; Tilak Raj Bhardwaj; Manoj Kumar
Journal:  Steroids       Date:  2009-10-30       Impact factor: 2.668

9.  Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.

Authors:  Martin Frotscher; Erika Ziegler; Sandrine Marchais-Oberwinkler; Patricia Kruchten; Alexander Neugebauer; Ludivine Fetzer; Christiane Scherer; Ursula Müller-Vieira; Josef Messinger; Hubert Thole; Rolf W Hartmann
Journal:  J Med Chem       Date:  2008-03-07       Impact factor: 7.446

10.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544
View more
  12 in total

1.  Electrophotocatalytic diamination of vicinal C-H bonds.

Authors:  Tao Shen; Tristan H Lambert
Journal:  Science       Date:  2021-02-04       Impact factor: 47.728

2.  Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1).

Authors:  Richard L Schroeder; Phan Tram; Jiawang Liu; Maryam Foroozesh; Jayalakshmi Sridhar
Journal:  Expert Opin Ther Pat       Date:  2015-10-29       Impact factor: 6.674

3.  Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.

Authors:  Simone Brixius-Anderko; Emily E Scott
Journal:  J Biol Chem       Date:  2018-11-13       Impact factor: 5.157

4.  Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Jörg Haupenthal; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2011-06-03       Impact factor: 4.345

5.  In vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites.

Authors:  Fabienne Barna; Karim Debache; Carsten A Vock; Tatiana Küster; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

6.  1-(1-Adamantylmeth-yl)-1H-benzimidazole.

Authors:  Jarmila Cernochová; Marek Nečas; Ivo Kuřitka; Robert Vícha
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-10-12

7.  Pharmacophore Modeling and in Silico/in Vitro Screening for Human Cytochrome P450 11B1 and Cytochrome P450 11B2 Inhibitors.

Authors:  Muhammad Akram; Watcharee Waratchareeyakul; Joerg Haupenthal; Rolf W Hartmann; Daniela Schuster
Journal:  Front Chem       Date:  2017-12-19       Impact factor: 5.221

8.  3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2.

Authors:  Lina Yin; Qingzhong Hu; Rolf W Hartmann
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

9.  C-H Amination via Electrophotocatalytic Ritter-type Reaction.

Authors:  Tao Shen; Tristan H Lambert
Journal:  J Am Chem Soc       Date:  2021-06-02       Impact factor: 16.383

Review 10.  Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.

Authors:  Angela Stefanachi; Francesco Leonetti; Leonardo Pisani; Marco Catto; Angelo Carotti
Journal:  Molecules       Date:  2018-01-27       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.